Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

NCT01309997 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Graft Versus Host Disease
Systemic Scleroderma

Interventions

DRUG: imatinib mesylate
BIOLOGICAL: rituximab

Sponsor

Lee, Stephanie

Collaborators

[object Object]